|
The following is the content for the January/February 2018 issue of IJPC.
Editorial: 2017-Some Good Things Happened and Some Others
Features:
- Certification, Accreditation, and Credentialing for 503A Compounding Pharmacies
- Systematic Review of Pharmacy Compounding of Pain Medication
- Government Affairs Lookback on 2017 Accomplishments and Look Ahead at 2018 Initiatives (IACP)
Basics:
- Basics of Compounding: Providing Pharmacy Services to BARIATRIC Surgery Patients (Nonsterile Basics)
- Relationship Between Syringe Size and Dosing Accuracy (Sterile Basics)
Calculations
Formulations:
- Glutamate and Aspartate Cardioplegia Additive Solution
- Mercaptopurine 50 mg/mL in Ora-Sweet:Ora-Plus Suspension
- Metronidazole 50 mg/mL in Ora-Blend Suspension
- Miconazole 10% in RECURA Topical Cream
- Naproxen 25 mg/mL in Oral Mix or Oral Mix SF
- Penicillamine-D 50 mg/mL in Syrspend SF PH4 Oral Suspension
- Ranitidine 15 mg/mL in SyrSpend SF PH4
- Sodium Citrate 9% Nasal Spray for Olfactory Disorders
- Thalidomide 20 mg/mL in Ora-Plus:Ora-Sweet Suspension
- Voriconazole 50-mg/mL Oral Suspension
Peer Review:
- Effects of Compounded Stanford Modified Oral Rinse (MucoLox) on the Survival and Migration of Oral Keratinocytes and Fibroblasts: Implications for Wound Healing
- Stability of an Alcohol-free, Dye-free Hydrocortisone (2 mg/mL) Compounded Oral Suspension
- Compatibility and Stability of VARUBI (Rolapitant) Injectable Emulsion Admixed with Intravenous Palonosetron Hydrochloride Injection and Dexamethasone Sodium Phosphate Injection
- Compatibility and Stability of VARUBI (Rolapitant) Injectable Emulsion Admixed with Intravenous Granisetron Hydrochloride
NOTE: If you wish to subscribe or need help navigating the online websites www.ijpc.com and/or www.compoundingtoday.com you can email Deb at dmehlhaff@ijpc.com or call the IJPC office between 9-4 CST at 800.757.4572 x1.
Loyd V. Allen, Jr., PhD, RPh
Editor-in-Chief
International Journal of Pharmaceutical Compounding
Remington: The Science and Practice of Pharmacy Twenty-second edition
|
|
News
"Gag Rule" Being Fought by Maryland Pharmacists
Officials in Maryland are trying to eliminate a "gag rule" that prevents pharmacists from telling consumers that they can pay less for their prescription drugs. If successful, Maryland would join five other states-Connecticut, Maine, Louisiana, North Dakota, and Georgia-that have banned the rule that some PBMs put in their contracts with pharmacies. "It is this problem of pharmacists being prohibited from telling people that the price is lower from out-of-pocket insurance price," says Vinny DeMarco, president of Maryland Citizens' Health Initiative, which is pushing the legislation this year. "Sometimes, pharmacists have gag orders and they can't tell the patient it is cheaper to pay cash than go through your plan. That is crazy," said Sen. Bill Cassidy (R-LA) in late December. "Louisiana has outlawed those, but in most states they are still allowed. There would be bipartisan support on that."
http://www.washingtonexaminer.com/maryland-to-fight-pharmacist-gag-rule-on-drug-costs/article/2645019
OTC Drugmaker Told to Separate the Weedkiller from the Oral Rinse
The FDA has sent a warning letter to the owner of Continental Manufacturing Chemist after an inspection of a plant in Madrid, Iowa, which makes earwax drops, oral rinse, and fluoride toothpastes, as well as lawn care and other products. During a visit in April 2017, investigators discovered that the facility wasn't physically separating the OTC products like the oral rinse from the weedkiller or adhesive remover and didn't even have quarantine markings to make sure products didn't get mixed up. In addition, the plant released at least three batches of oral rinse and two batches of fluoride toothpaste without the products being reviewed by the quality unit.
https://www.fiercepharma.com/manufacturing/separate-weed-killer-from-oral-rinse-fda-tells-otc-maker
Teva Cutting up to 40 Manufacturing Sites
Teva now has agreements with workers to close another plant in Israel. That is two down and about 40 to go. Recently, workers walked off the lines after new CEO K�re Schultz said that Teva would cut about 14,000 positions worldwide, with about 1,750 cuts coming from Israel. The financially distressed generics company scrambles to fix big problems.
https://www.fiercepharma.com/manufacturing/teva-to-cut-up-to-40-manufacturing-sites-25-slated-to-go-next-2-years
|
|
Did You Know ...
�that when we purchased our first house back in the 70's, our home mortgage rate was about 12%? A few years ago these rates were down to about 1% to 2%; now purchasers shop around for something in the 3% to 4% range.
Today's prime rate is in the vicinity of 4.5% and credit card rates are from 12% to 27%. CD rates range from 0.01% to 2.00%.
|
